Skip to main content
. 2021 Aug 26;12:5148. doi: 10.1038/s41467-021-25412-x

Fig. 5. Pharmacological inhibition of AHR limits CoVs replication in vitro.

Fig. 5

a Huh 7.5, Vero, and Calu-3 cells were pretreated with the indicated concentrations of the AHR antagonist CH22319 and cell viability was determined using an MTS assay. Data represent the mean ± SD (n = 3 independent experiments). p values were determined by a one-way ANOVA followed by Tukey’s post-hoc test. b Huh 7.5 cells were pretreated with the indicated concentrations of the AHR antagonist CH223191 and infected with HCoV-229E (MOI = 0.1); 72 h p.i. CPE was quantified. Data represent the mean ± SD (n = 3 independent experiments). p values were determined by a one-way ANOVA followed by Tukey’s post-hoc test. c Calu-3 cells were pretreated with the indicated concentrations of CH223191 and infected with SARS-CoV-2 at the indicated MOI; 48 h p.i. supernatants were harvested for quantification of the viral titer. Data represent the mean ± SD (n = 3 independent experiments). p values were determined by a one-way ANOVA followed by Tukey’s post-hoc test. d Vero cells were used as described in (c). Data represent the mean ± SD (n = 3 independent experiments). p values were determined by a one-way ANOVA followed by Tukey’s post-hoc test. Source data are provided as a Source Data file.